
Heartseed is a biotechnology company that develops iPSC-derived cardiomyocytes for the treatment of heart failure.
heartseed.jpCrawled Nov 5, 2026
Heartseed develops regenerative heart treatments using iPS cells, based on technology from Keio University’s Department of Cardiovascular Medicine.
Heartseed develops regenerative heart treatments using iPS cells, based on technology from Keio University’s Department of Cardiovascular Medicine.
The company focuses on cardiovascular disease, the world’s leading cause of death, to advance regenerative medicine treatments for intractable conditions.
Heartseed reports promising one-year results for its open-chest heart cell therapy. The company is now enrolling patients for a catheter-based delivery method, expanding its clinical approach.
Novo Nordisk terminates its $598 million partnership with Heartseed, halting development of the iPSC-derived heart failure therapy **HS-001**. The collaboration, initiated in 2021, targeted an allogeneic stem cell treatment for heart failure patients. The move signals a strategic pivot in Novo Nordisk’s regenerative medicine and induced pluripotent stem cell (iPSC) research focus.
Novo Nordisk cancels a $598 million partnership with cell therapy firm Heartseed as part of a strategic overhaul led by its new CEO. The move ends a four-year collaboration, signaling a shift in the company’s focus under recent leadership changes. The restructuring reflects Novo Nordisk’s broader efforts to reallocate resources amid evolving priorities in its pipeline.
Novo Nordisk terminates its $598 million cell therapy partnership with Heartseed as part of a broader restructuring under new CEO Maziar Mike Doustdar. The move cancels a high-value collaboration focused on heart failure treatments. Novo’s restructuring impacts multiple initiatives, including this major alliance.
Heartseed secures $26 million in funding to advance its stem cell injection therapy for treating heart failure. The company plans to use the capital to further develop and test its stem cell-based approach. This funding supports research into potential regenerative treatments for patients with heart failure.